Comparison
BPC-157 vs TB-500
Two research compounds discussed interchangeably for tissue repair. Their mechanisms, their evidence bases and their regulatory positions are not the same.
Comparison
Tesamorelin vs CJC-1295
Tesamorelin and CJC-1295 are both analogs of growth hormone-releasing hormone. They stimulate the same receptor on the same cells to produce the same hormonal response. Their similarity is what makes the comparison useful: it isolates the one variable that actually distinguishes them, which is whether anyone completed the work of finding out what the compound does to people.
Side by side
Every row is traceable to the linked compound profile. Note that this table has no “best for” row: framing investigational compounds that way reads as a treatment recommendation, so we compare primary areas of research instead.
| Attribute | TesamorelinFDA approved | CJC-1295Not FDA approved |
|---|---|---|
| Mechanism | GHRH receptor agonist | GHRH receptor agonist, albumin-bound for long duration |
| Primary area of research | Visceral adipose tissue reduction in HIV-associated lipodystrophy | Growth hormone axis pharmacology in healthy adults |
| Research stage | FDA Approved | Clinical Research |
| Overall evidence level | CLINICAL | EARLY CLINICAL |
| Highest trial phase completed | Phase 3, leading to approval | Phase 1 |
| Endpoint tested | Visceral adipose tissue, measured by imaging (clinical) | GH and IGF-1 concentrations (surrogate) |
| Labelled warnings | Neoplasms, IGF-1 elevation, fluid retention, glucose intolerance and diabetes, hypersensitivity, mortality in acute critical illness | None — no approved label exists |
| Stated limitations of use | Not indicated for weight loss management; long-term cardiovascular safety not established | Not applicable — no approved indication |
| FDA approval | Yes, for one narrow indication | No |
| Principal open question | Do the surrogate improvements translate into long-term cardiovascular benefit? | Everything downstream of hormone concentrations remains untested. |
Same mechanism, different knowledge
Because these two compounds act the same way, the tesamorelin label functions as the best available guide to what GHRH-analog pharmacology does in humans over time. It lists neoplasm risk, unknown consequences of prolonged IGF-1 elevation, fluid retention, glucose intolerance and diabetes, hypersensitivity reactions, and increased mortality in acute critical illness.
Those findings did not come from theory. They came from a development programme that administered the drug to people, watched carefully, and recorded what happened.
CJC-1295 stimulates the same receptor and has no such record. The absence of a warning list is not the absence of risk; it is the absence of the process that produces warning lists.
What "approved" bought
Tesamorelin's approval covers the reduction of excess abdominal fat in adults with HIV and lipodystrophy. Not weight loss. Not body composition in general. Not ageing. The label states the exclusions explicitly, and the FDA required them to remain because the evidence did not support removing them.
An approval this narrow, after a full Phase 3 programme, is a useful calibration for how much evidence it takes to say something definite about a compound in this class — and how little of that evidence exists for the unapproved alternatives.
Where CJC-1295 stopped
Randomised, placebo-controlled Phase 1 studies in healthy adults established that the compound raises GH and IGF-1 for days after a single injection, with an estimated half-life of 5.8 to 8.1 days. Then the published record ends.
No Phase 2 with a clinical endpoint. No Phase 3. No active programme we have identified. The compound is now sold as a research chemical, on the strength of a Phase 1 result that was never followed up.
For more on how this class reads as a whole, see growth hormone secretagogues: what the human evidence shows.
Frequently asked questions
Is CJC-1295 just an unapproved version of tesamorelin?
They are different molecules with the same receptor target. Tesamorelin has a completed development programme, an approval and a full safety label. CJC-1295 has Phase 1 pharmacology data and nothing after it.
Do the tesamorelin warnings apply to CJC-1295?
Formally, no — warnings belong to approved labels, and CJC-1295 has none. Pharmacologically, the mechanism is shared, so the questions the tesamorelin label raises are the questions nobody has answered for CJC-1295.
Is tesamorelin approved for weight loss?
No. The label states explicitly that it is not indicated for weight loss management, and that its effect on body weight is neutral.
Other comparisons
Comparison
CJC-1295 vs Ipamorelin
Two growth hormone secretagogues with different receptors and very different evidence. One has Phase 1 hormone data; the other has a published Phase 2 trial that missed its endpoint.
Comparison
Semaglutide vs Tirzepatide vs Retatrutide
One, two and three receptors. Two approved drugs and one investigational compound. What the trials measured, what the labels say, and where the differences actually lie.
References
Peptide Insider cites primary sources wherever they exist — regulatory documents, trial registrations and peer-reviewed literature — in preference to secondary summaries.
- 1.U.S. Food and Drug Administration. EGRIFTA (tesamorelin for injection) — Highlights of Prescribing Information. FDA Drugs@FDA, 2019;NDA 022505.Regulatory
- 2.Teichman SL, Neale A, Lawrence B, et al.. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. The Journal of Clinical Endocrinology & Metabolism, 2006;91(3):799–805.